English
简体中文
Total: £ 56.28
Published Date: 2025-06-12 | Pages: 132 | Tables: 131 | Medical Care
In 2024, the global market size of Prostate Cancer Diagnostics was estimated to be worth US$ 15590 million and is forecast to reach approximately US$ 26180 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics.
The Prostate Cancer Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Prostate Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prostate Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segment by Application
Age Below 55
Age 55-75
Age Above 75
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Prostate Cancer Diagnostics in global and regional level.
Chapter 3: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Diagnostics revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Prostate Cancer Diagnostics Product Introduction
1.2 Market by Type
1.2.1 Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Tumor Biomarker Tests
1.2.3 Imaging
1.2.4 Biopsy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Age Below 55
1.3.3 Age 55-75
1.3.4 Age Above 75
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Prostate Cancer Diagnostics Market Size Estimates and Forecasts
2.2 Prostate Cancer Diagnostics Market Size by Region: 2024 Versus 2031
2.2.1 Global Prostate Cancer Diagnostics Revenue by Region: 2020-2025
2.2.2 Global Prostate Cancer Diagnostics Revenue Forecast by Region (2026-2031)
2.2.3 Global Prostate Cancer Diagnostics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Prostate Cancer Diagnostics Revenue by Type (2020-2031)
3.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Prostate Cancer Diagnostics Revenue by Application (2020-2031)
3.2.2 Global Prostate Cancer Diagnostics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Tumor Biomarker Tests of Prostate Cancer Diagnostics Revenue Market Share by Application
3.3.2 Imaging of Prostate Cancer Diagnostics Revenue Market Share by Application
3.3.3 Biopsy of Prostate Cancer Diagnostics Revenue Market Share by Application
3.3.4 Other of Prostate Cancer Diagnostics Revenue Market Share by Application
4 Global Prostate Cancer Diagnostics by Company
4.1 Global Prostate Cancer Diagnostics Revenue by Company (2020-2025)
4.2 Global Prostate Cancer Diagnostics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Prostate Cancer Diagnostics Companies around the World: Ranking by Revenue
4.3.2 Global Prostate Cancer Diagnostics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Prostate Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Prostate Cancer Diagnostics Companies Headquarters & Product Type
4.4.1 Global Prostate Cancer Diagnostics Companies Headquarters
4.4.2 Date of International Companies Enter into Prostate Cancer Diagnostics Market
4.4.3 Global Prostate Cancer Diagnostics Companies Product & Service
4.4.4 Tumor Biomarker Tests Revenue Market Share of Prostate Cancer Diagnostics by Company
4.4.5 Imaging Revenue Market Share of Prostate Cancer Diagnostics by Company
4.4.6 Biopsy Revenue Market Share of Prostate Cancer Diagnostics by Company
4.4.7 Other Revenue Market Share of Prostate Cancer Diagnostics by Company
4.5 Global Prostate Cancer Diagnostics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 OPKO
5.1.1 OPKO Corporation Information
5.1.2 OPKO Description, Business Overview
5.1.3 OPKO Prostate Cancer Diagnostics Products Offered
5.1.4 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.1.5 OPKO Prostate Cancer Diagnostics Revenue by Product in 2024
5.1.6 OPKO Prostate Cancer Diagnostics Revenue by Application in 2024
5.1.7 OPKO Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.1.8 OPKO Recent Developments
5.2 Genomic Health
5.2.1 Genomic Health Corporation Information
5.2.2 Genomic Health Description, Business Overview
5.2.3 Genomic Health Prostate Cancer Diagnostics Products Offered
5.2.4 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.2.5 Genomic Health Prostate Cancer Diagnostics Revenue by Product in 2024
5.2.6 Genomic Health Prostate Cancer Diagnostics Revenue by Application in 2024
5.2.7 Genomic Health Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.2.8 Genomic Health Recent Developments
5.3 Abbott
5.3.1 Abbott Corporation Information
5.3.2 Abbott Description, Business Overview
5.3.3 Abbott Prostate Cancer Diagnostics Products Offered
5.3.4 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.3.5 Abbott Prostate Cancer Diagnostics Revenue by Product in 2024
5.3.6 Abbott Prostate Cancer Diagnostics Revenue by Application in 2024
5.3.7 Abbott Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.3.8 Abbott Recent Developments
5.4 Beckman Coulter
5.4.1 Beckman Coulter Corporation Information
5.4.2 Beckman Coulter Description, Business Overview
5.4.3 Beckman Coulter Prostate Cancer Diagnostics Products Offered
5.4.4 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.4.5 Beckman Coulter Prostate Cancer Diagnostics Revenue by Product in 2024
5.4.6 Beckman Coulter Prostate Cancer Diagnostics Revenue by Application in 2024
5.4.7 Beckman Coulter Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.4.8 Beckman Coulter Recent Developments
5.5 Siemens Healthcare
5.5.1 Siemens Healthcare Corporation Information
5.5.2 Siemens Healthcare Description, Business Overview
5.5.3 Siemens Healthcare Prostate Cancer Diagnostics Products Offered
5.5.4 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.5.5 Siemens Healthcare Prostate Cancer Diagnostics Revenue by Product in 2024
5.5.6 Siemens Healthcare Prostate Cancer Diagnostics Revenue by Application in 2024
5.5.7 Siemens Healthcare Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.5.8 Siemens Healthcare Recent Developments
5.6 bioMeriux
5.6.1 bioMeriux Corporation Information
5.6.2 bioMeriux Description, Business Overview
5.6.3 bioMeriux Prostate Cancer Diagnostics Products Offered
5.6.4 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.6.5 bioMeriux Prostate Cancer Diagnostics Revenue by Product in 2024
5.6.6 bioMeriux Prostate Cancer Diagnostics Revenue by Application in 2024
5.6.7 bioMeriux Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.6.8 bioMeriux Recent Developments
5.7 Roche
5.7.1 Roche Corporation Information
5.7.2 Roche Description, Business Overview
5.7.3 Roche Prostate Cancer Diagnostics Products Offered
5.7.4 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.7.5 Roche Prostate Cancer Diagnostics Revenue by Product in 2024
5.7.6 Roche Prostate Cancer Diagnostics Revenue by Application in 2024
5.7.7 Roche Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.7.8 Roche Recent Developments
5.8 MDx Health
5.8.1 MDx Health Corporation Information
5.8.2 MDx Health Description, Business Overview
5.8.3 MDx Health Prostate Cancer Diagnostics Products Offered
5.8.4 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.8.5 MDx Health Prostate Cancer Diagnostics Revenue by Product in 2024
5.8.6 MDx Health Prostate Cancer Diagnostics Revenue by Application in 2024
5.8.7 MDx Health Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.8.8 MDx Health Recent Developments
5.9 DiaSorin
5.9.1 DiaSorin Corporation Information
5.9.2 DiaSorin Description, Business Overview
5.9.3 DiaSorin Prostate Cancer Diagnostics Products Offered
5.9.4 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.9.5 DiaSorin Prostate Cancer Diagnostics Revenue by Product in 2024
5.9.6 DiaSorin Prostate Cancer Diagnostics Revenue by Application in 2024
5.9.7 DiaSorin Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.9.8 DiaSorin Recent Developments
5.10 Myriad Genetics
5.10.1 Myriad Genetics Corporation Information
5.10.2 Myriad Genetics Description, Business Overview
5.10.3 Myriad Genetics Prostate Cancer Diagnostics Products Offered
5.10.4 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.10.5 Myriad Genetics Prostate Cancer Diagnostics Revenue by Product in 2024
5.10.6 Myriad Genetics Prostate Cancer Diagnostics Revenue by Application in 2024
5.10.7 Myriad Genetics Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.10.8 Myriad Genetics Recent Developments
5.11 Ambry Genetics
5.11.1 Ambry Genetics Corporation Information
5.11.2 Ambry Genetics Description, Business Overview
5.11.3 Ambry Genetics Prostate Cancer Diagnostics Products Offered
5.11.4 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2020-2025)
5.11.5 Ambry Genetics Prostate Cancer Diagnostics Revenue by Product in 2024
5.11.6 Ambry Genetics Prostate Cancer Diagnostics Revenue by Application in 2024
5.11.7 Ambry Genetics Prostate Cancer Diagnostics Revenue by Geographic Area in 2024
5.11.8 Ambry Genetics Recent Developments
6 North America
6.1 North America Prostate Cancer Diagnostics Market Size YoY Growth 2020-2031
6.2 North America Prostate Cancer Diagnostics Market Facts & Figures by Country (2020-2031)
6.3 North America Prostate Cancer Diagnostics Revenue by Type (2020-2025)
6.4 North America Prostate Cancer Diagnostics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Prostate Cancer Diagnostics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Prostate Cancer Diagnostics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Prostate Cancer Diagnostics Revenue by Type (2020-2025)
7.4 Asia-Pacific Prostate Cancer Diagnostics Revenue by Application (2020-2025)
8 Europe
8.1 Europe Prostate Cancer Diagnostics Market Size YoY Growth 2020-2031
8.2 Europe Prostate Cancer Diagnostics Market Facts & Figures by Country (2020-2031)
8.3 Europe Prostate Cancer Diagnostics Revenue by Type (2020-2025)
8.4 Europe Prostate Cancer Diagnostics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Prostate Cancer Diagnostics Market Size YoY Growth 2020-2031
9.2 Latin America Prostate Cancer Diagnostics Market Facts & Figures by Country (2020-2031)
9.3 Latin America Prostate Cancer Diagnostics Revenue by Type (2020-2025)
9.4 Latin America Prostate Cancer Diagnostics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Prostate Cancer Diagnostics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Prostate Cancer Diagnostics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Prostate Cancer Diagnostics Revenue by Type (2020-2025)
10.4 Middle East and Africa Prostate Cancer Diagnostics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Prostate Cancer Diagnostics Supply Chain Analysis
11.2 Prostate Cancer Diagnostics Key Raw Materials and Upstream Suppliers
11.3 Prostate Cancer Diagnostics Clients Analysis
11.4 Prostate Cancer Diagnostics Sales Channel and Sales Model Analysis
11.4.1 Prostate Cancer Diagnostics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Prostate Cancer Diagnostics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Prostate Cancer Diagnostics Distributors
12 Prostate Cancer Diagnostics Market Dynamics
12.1 Prostate Cancer Diagnostics Industry Trends
12.2 Prostate Cancer Diagnostics Market Drivers
12.3 Prostate Cancer Diagnostics Market Challenges
12.4 Prostate Cancer Diagnostics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Prostate Cancer Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Prostate Cancer Diagnostics Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Prostate Cancer Diagnostics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Prostate Cancer Diagnostics Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Prostate Cancer Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Prostate Cancer Diagnostics Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Prostate Cancer Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Prostate Cancer Diagnostics Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Prostate Cancer Diagnostics Revenue by Company (2020-2025) & (US$ Million)
Table 11. Prostate Cancer Diagnostics Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Prostate Cancer Diagnostics Players by Revenue (US$ Million) in 2024
Table 13. Global Prostate Cancer Diagnostics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Prostate Cancer Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer Diagnostics as of 2024)
Table 15. Global Prostate Cancer Diagnostics Companies Headquarters
Table 16. Date of International Companies Enter into Prostate Cancer Diagnostics Market
Table 17. Global Prostate Cancer Diagnostics Companies Product & Service
Table 18. Global Prostate Cancer Diagnostics Mergers & Acquisitions, Expansion Plans
Table 19. OPKO Corporation Information
Table 20. OPKO Description and Business Overview
Table 21. OPKO Prostate Cancer Diagnostics Product
Table 22. OPKO Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. OPKO Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 24. OPKO Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 25. OPKO Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 26. OPKO Recent Developments
Table 27. Genomic Health Corporation Information
Table 28. Genomic Health Description and Business Overview
Table 29. Genomic Health Prostate Cancer Diagnostics Product
Table 30. Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Genomic Health Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 32. Genomic Health Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 33. Genomic Health Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 34. Genomic Health Recent Developments
Table 35. Abbott Corporation Information
Table 36. Abbott Description and Business Overview
Table 37. Abbott Prostate Cancer Diagnostics Product
Table 38. Abbott Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Abbott Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 40. Abbott Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 41. Abbott Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 42. Abbott Recent Developments
Table 43. Beckman Coulter Corporation Information
Table 44. Beckman Coulter Description and Business Overview
Table 45. Beckman Coulter Prostate Cancer Diagnostics Product
Table 46. Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Beckman Coulter Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 48. Beckman Coulter Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 49. Beckman Coulter Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 50. Beckman Coulter Recent Developments
Table 51. Siemens Healthcare Corporation Information
Table 52. Siemens Healthcare Description and Business Overview
Table 53. Siemens Healthcare Prostate Cancer Diagnostics Product
Table 54. Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Siemens Healthcare Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 56. Siemens Healthcare Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 57. Siemens Healthcare Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 58. Siemens Healthcare Recent Developments
Table 59. bioMeriux Corporation Information
Table 60. bioMeriux Description and Business Overview
Table 61. bioMeriux Prostate Cancer Diagnostics Product
Table 62. bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. bioMeriux Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 64. bioMeriux Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 65. bioMeriux Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 66. bioMeriux Recent Developments
Table 67. Roche Corporation Information
Table 68. Roche Description and Business Overview
Table 69. Roche Prostate Cancer Diagnostics Product
Table 70. Roche Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Roche Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 72. Roche Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 73. Roche Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 74. Roche Recent Developments
Table 75. MDx Health Corporation Information
Table 76. MDx Health Description and Business Overview
Table 77. MDx Health Prostate Cancer Diagnostics Product
Table 78. MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. MDx Health Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 80. MDx Health Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 81. MDx Health Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 82. MDx Health Recent Developments
Table 83. DiaSorin Corporation Information
Table 84. DiaSorin Description and Business Overview
Table 85. DiaSorin Prostate Cancer Diagnostics Product
Table 86. DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. DiaSorin Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 88. DiaSorin Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 89. DiaSorin Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 90. DiaSorin Recent Developments
Table 91. Myriad Genetics Corporation Information
Table 92. Myriad Genetics Description and Business Overview
Table 93. Myriad Genetics Prostate Cancer Diagnostics Product
Table 94. Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Myriad Genetics Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 96. Myriad Genetics Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 97. Myriad Genetics Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 98. Myriad Genetics Recent Developments
Table 99. Ambry Genetics Corporation Information
Table 100. Ambry Genetics Description and Business Overview
Table 101. Ambry Genetics Prostate Cancer Diagnostics Product
Table 102. Ambry Genetics Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Ambry Genetics Revenue Proportion of Prostate Cancer Diagnostics by Product in 2024
Table 104. Ambry Genetics Revenue Proportion of Prostate Cancer Diagnostics by Application in 2024
Table 105. Ambry Genetics Revenue Proportion of Prostate Cancer Diagnostics by Geographic Area in 2024
Table 106. Ambry Genetics Recent Developments
Table 107. North America Prostate Cancer Diagnostics Revenue by Country (2020-2025) & (US$ Million)
Table 108. North America Prostate Cancer Diagnostics Revenue by Country (2026-2031) & (US$ Million)
Table 109. North America Prostate Cancer Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 110. North America Prostate Cancer Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 111. Asia-Pacific Prostate Cancer Diagnostics Revenue by Region (2020-2025) & (US$ Million)
Table 112. Asia-Pacific Prostate Cancer Diagnostics Revenue by Region (2026-2031) & (US$ Million)
Table 113. Asia-Pacific Prostate Cancer Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 114. Asia-Pacific Prostate Cancer Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 115. Europe Prostate Cancer Diagnostics Revenue by Country (2020-2025) & (US$ Million)
Table 116. Europe Prostate Cancer Diagnostics Revenue by Country (2026-2031) & (US$ Million)
Table 117. Europe Prostate Cancer Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 118. Europe Prostate Cancer Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 119. Latin America Prostate Cancer Diagnostics Revenue by Country (2020-2025) & (US$ Million)
Table 120. Latin America Prostate Cancer Diagnostics Revenue by Country (2026-2031) & (US$ Million)
Table 121. Latin America Prostate Cancer Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 122. Latin America Prostate Cancer Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 123. Middle East and Africa Prostate Cancer Diagnostics Revenue by Country (2020-2025) & (US$ Million)
Table 124. Middle East and Africa Prostate Cancer Diagnostics Revenue by Country (2026-2031) & (US$ Million)
Table 125. Middle East and Africa Prostate Cancer Diagnostics Revenue by Type (2020-2025) & (US$ Million)
Table 126. Middle East and Africa Prostate Cancer Diagnostics Revenue by Application (2020-2025) & (US$ Million)
Table 127. Prostate Cancer Diagnostics Key Raw Materials, Industry Status and Trend
Table 128. Prostate Cancer Diagnostics Key Raw Materials and Upstream Suppliers
Table 129. Prostate Cancer Diagnostics Clients Status and Trend
Table 130. Prostate Cancer Diagnostics Typical Clients
Table 131. Prostate Cancer Diagnostics Distributors
Table 132. Prostate Cancer Diagnostics Market Trends
Table 133. Prostate Cancer Diagnostics Market Drivers
Table 134. Prostate Cancer Diagnostics Market Challenges
Table 135. Prostate Cancer Diagnostics Market Restraints
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Prostate Cancer Diagnostics Product Picture
Figure 2. Global Prostate Cancer Diagnostics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Prostate Cancer Diagnostics Revenue Market Share by Type in 2024 & 2031
Figure 4. Tumor Biomarker Tests Product Picture
Figure 5. Imaging Product Picture
Figure 6. Biopsy Product Picture
Figure 7. Other Product Picture
Figure 8. Global Prostate Cancer Diagnostics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 9. Global Prostate Cancer Diagnostics Revenue Market Share by Application in 2024 & 2031
Figure 10. Age Below 55
Figure 11. Age 55-75
Figure 12. Age Above 75
Figure 13. Prostate Cancer Diagnostics Report Years Considered
Figure 14. Global Prostate Cancer Diagnostics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Prostate Cancer Diagnostics Market Size (2020-2031) & (US$ Million)
Figure 16. Global Prostate Cancer Diagnostics Market Size Market Share by Region: 2024 Versus 2031
Figure 17. Global Prostate Cancer Diagnostics Revenue Market Share by Region (2020-2031)
Figure 18. Global Prostate Cancer Diagnostics Revenue Market Share Forecast by Type (2020-2031)
Figure 19. Global Prostate Cancer Diagnostics Revenue Market Share Forecast by Application (2020-2031)
Figure 20. Tumor Biomarker Tests of Prostate Cancer Diagnostics Revenue Market Share by Application, 2024 VS 2031
Figure 21. Imaging of Prostate Cancer Diagnostics Revenue Market Share by Application, 2024 VS 2031
Figure 22. Biopsy of Prostate Cancer Diagnostics Revenue Market Share by Application, 2024 VS 2031
Figure 23. Other of Prostate Cancer Diagnostics Revenue Market Share by Application, 2024 VS 2031
Figure 24. Prostate Cancer Diagnostics Revenue Share by Company (2024)
Figure 25. Prostate Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 26. Tumor Biomarker Tests Revenue Proportion by Company in 2024
Figure 27. Imaging Revenue Proportion by Company in 2024
Figure 28. Biopsy Revenue Proportion by Company in 2024
Figure 29. Other Revenue Proportion by Company in 2024
Figure 30. North America Prostate Cancer Diagnostics Revenue 2020-2031 (US$ Million)
Figure 31. North America Prostate Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Figure 32. North America Prostate Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Figure 33. Asia-Pacific Prostate Cancer Diagnostics Revenue 2020-2031 (US$ Million)
Figure 34. Asia-Pacific Prostate Cancer Diagnostics Revenue Market Share by Region (2020-2031)
Figure 35. Asia-Pacific Prostate Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Figure 36. Asia-Pacific Prostate Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Figure 37. Europe Prostate Cancer Diagnostics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Europe Prostate Cancer Diagnostics Revenue Market Share by Country (2020-2031)
Figure 39. Europe Prostate Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Figure 40. Europe Prostate Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Figure 41. Latin America Prostate Cancer Diagnostics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Latin America Prostate Cancer Diagnostics Revenue Market Share by Country (2020-2031)
Figure 43. Latin America Prostate Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Figure 44. Latin America Prostate Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Figure 45. Middle East and Africa Prostate Cancer Diagnostics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 46. Middle East and Africa Prostate Cancer Diagnostics Revenue Market Share by Country (2020-2031)
Figure 47. Middle East and Africa Prostate Cancer Diagnostics Revenue Market Share by Type (2020-2025)
Figure 48. Middle East and Africa Prostate Cancer Diagnostics Revenue Market Share by Application (2020-2025)
Figure 49. Prostate Cancer Diagnostics Supply Chain (Upstream and Downstream Market)
Figure 50. Global Production Market Share of Prostate Cancer Diagnostics Raw Materials by Region in 2024
Figure 51. Prostate Cancer Diagnostics Distribution Channels
Figure 52. Global Prostate Cancer Diagnostics Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 53. Global Prostate Cancer Diagnostics Percentage 2020-2031: Online Sales VS Offline Sales
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
